Vapendavir
Rhinovirus infection, to reduce acute exacerbations in asthma/COPD patients
- CAS No.
- 439085-51-5
- Indication Class
- Anti-infectives
- Patent Expiry
- To be assessed
- Therapeutic Area
- Anti-infective / Respiratory
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A capsid-binding inhibitor of rhinovirus that can reduce hospitalizations from COPD/asthma exacerbations, a scarce causal-therapy attempt in respiratory care.
Anti-infective / Respiratory · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Vapendavir is an antiviral drug under development specifically for the treatment of human rhinovirus (HRV) infection. Its mechanism of action is to bind to the viral capsid (VP1), preventing the virus from entering and infecting cells.
Supply source: Unibest · Vapendavir, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.